



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

7th August 2025
IOLCP/CGC/2025

National Stock Exchange of India Ltd

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Security Code: 524164

Subject: Press Release – Financial Results for the quarter ended 30th June 2025

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed a Press Release dated 7th August 2025 with respect to financial results for the quarter ended 30th June 2025.

Hope you will find the same in order.

Thanking You,

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh
Sr. Vice President & Company Secretary



IOL Chemicals And Pharmaceuticals Limited




IOL Chemicals & Pharmaceuticals Limited Reports Robust Q1 FY26 Performance

Strong Execution Drives Revenue, EBITDA, and PAT Growth in a Challenging Market Landscape

Ludhiana, 07th August 2025: IOL Chemicals & Pharmaceuticals Ltd., one of the leading manufacturers of Bulk Drugs & Specialty Chemicals announced its Financial Results for the quarter ended on 30th June 2025.

Q1 FY26 Financial Performance Snapshot

(Standalone)

Revenue from Operations ₹ 551.7 Cr  9.8%	EBITDA ₹ 69.5 Cr  19.5%	Profit After Tax ₹ 34.0 Cr  14.4%
--	---	---



Key Standalone Financial Highlights

Particulars (₹ Cr)	Q1 FY26	Q1 FY25	Y-o-Y	Q4 FY25	FY25
Revenue from Operations	551.7	502.4	9.8%	527.8	2,079.2
EBITDA	69.5	58.2	19.5%	67.5	224.6
EBITDA Margin (%)	12.4%	11.4%	+102 bps	12.7%	10.7%
Profit After Tax	34.0	29.7	14.4%	31.6	101.0
PAT Margin (%)	6.1%	5.8%	+25 bps	5.9%	4.8%
Cash Profit After Tax*	54.8	47.3	16.0%	56.4	185.1

* Profit Before Tax + Depreciation- Current Tax

Segment Highlights

(In ₹ Cr)



— EBIT — Revenue



IOL Chemicals And Pharmaceuticals Limited

Q1 FY26 Operational Highlights

- Successfully obtained REACH registration under EU regulations for Acetic Anhydride, enabling exports across EU markets
- Initiated a ₹5.5 crore project to set up Unit 9B for dedicated manufacturing of Minoxidil and its intermediates; expected completion by December 2025
- Majority of non-Ibuprofen APIs are operating at utilization levels of 65–70%+, with select products exceeding 90%, indicating strong demand and efficient capacity use
- Earned EcoVadis Silver Medal, placing IOL among the top 15% of companies globally for environmental, social, and ethical performance.

Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said,

“We are delighted to report an outstanding start to FY26, with Q1 results reflecting strong execution and strategic clarity. Despite challenging macroeconomic Conditions and pricing pressures, with several key product prices having bottomed out, IOL has delivered impressive performance, underscoring the resilience of our integrated business model.

Our continued focus on portfolio diversification is yielding results, with non-Ibuprofen APIs gaining traction across global markets. With the commissioning of our fully backward-integrated Paracetamol production unit, we are increasing our presence in both regulated and non-regulated markets. This positions us well to capture emerging opportunities, especially in regions where quality and compliance remain key differentiators.



In the chemicals segment, the successful REACH registration of Acetic Anhydride under EU norms opens up new growth avenues in Europe, reinforcing our commitment to global standards and market expansion. As we move forward, our priorities remain clear — to scale high-value APIs, deepen our export footprint, and drive operational excellence. With a robust balance sheet and a strong innovation pipeline, we are confident in our ability to deliver sustainable growth and long-term value for all stakeholders.”

About IOL Chemicals & Pharmaceuticals Ltd.

IOL Chemicals and Pharmaceuticals Ltd. (IOLCP), established in 1986 and headquartered in Ludhiana, Punjab, is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. It is the world’s largest producer of Ibuprofen with a 30% global market share, the second-largest global producer of Iso Butyl Benzene (IBB), and a key manufacturer of Ethyl Acetate in India. IOLCP’s API portfolio spans key therapeutic areas such as pain management, anti-convulsants, anti-diabetics, and cardiovascular care. With exports to over 80 countries—including the USA, UK, China, and Germany—and strong regulatory approvals, the company is well-positioned for global growth. Its backward-integrated operations and ongoing capacity expansion support long-term scalability and resilience.



Contact Details

IOL Chemicals & Pharmaceuticals Ltd.	Investor Relations: MUFG Intime India Pvt. Ltd.
	
CIN: L24116PB1986PLC007030	Ms. Prachi Ambre prachi.ambre@in.mpms.mufg.com
Mr. Abhay Raj Singh Sr. VP & Company Secretary investor@iolcp.com	Mr. Irfan Raeen irfan.raeen@in.mpms.mufg.com
	Meeting Request Link Website: https://in.mpms.mufg.com/

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.